Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31169366 | 1.00 | GBA1 (0.36) | GBA1HSD17B10ALDH1A1KDM4EATM | |
| SCHEMBL15001188 | 0.82 | GBA1 (0.35) | GBA1ALDH1A1KDM4EADRA2AADRA2B | |
| SCHEMBL15001209 | 0.82 | GBA1 (0.35) | GBA1ALDH1A1KDM4EADRA2AADRA2B | |
| SCHEMBL15001190 | 0.82 | GBA1 (0.35) | GBA1ALDH1A1KDM4EADRA2AADRA2B | |
| SCHEMBL210731 | 0.80 | GBA1 (0.35) | GBA1ALDH1A1KDM4EATMRAB9A | |
| SCHEMBL1818566 | 0.79 | GBA1 (0.41) | GBA1ALDH1A1KDM4EATMRAB9A | |
| SCHEMBL19062001 | 0.79 | GBA1 (0.33) | GBA1ALDH1A1KDM4EADRA2AADRA2B | |
| SCHEMBL29926723 | 0.79 | GBA1 (0.41) | GBA1ALDH1A1KDM4ERAB9ANPC1 | |
| SCHEMBL681100 | 0.79 | GBA1 (0.41) | GBA1ALDH1A1KDM4ERAB9ANPC1 | |
| SCHEMBL3509480 | 0.78 | GBA1 (0.33) | GBA1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358929-B2 | NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2025-07-15 | — | — | US | disclosed |
| US-20250059172-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL | NIPPON SHINYAKU CO., LTD. (JP) | 2025-02-20 | — | — | US | disclosed |
| EP-4458810-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL | Nippon Shinyaku Co., Ltd. (JP) | 2024-11-06 | — | — | EP | disclosed |
| US-20240294546-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2024-09-05 | — | — | US | disclosed |
| EP-3558318-B1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-12-20 | — | — | EP | disclosed |
| US-11807650-B2 | NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2023-11-07 | — | — | US | disclosed |
| US-11807650-B2 | NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2023-11-07 | — | — | US | disclosed |
| US-11807650-B2 | NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2023-11-07 | — | — | US | disclosed |
| WO-2023127883-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL | 日本新薬株式会社 | 2023-07-06 | — | — | WO | disclosed |
| US-20220153755-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2022-05-19 | — | — | US | disclosed |
| US-20120220581-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | JANSSEN-CILAG, S.A. (ES) | 2012-08-30 | — | — | US | disclosed |
| US-20120220581-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | JANSSEN-CILAG, S.A. (ES) | 2012-08-30 | — | — | US | disclosed |
| WO-2012087881-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20120157430-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2012-06-21 | — | — | US | disclosed |
| US-20110269752-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | PASTOR-FERNANDEZ JOAQUIN | 2011-11-03 | — | — | US | disclosed |
| US-20110269752-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | PASTOR-FERNANDEZ JOAQUIN | 2011-11-03 | — | — | US | disclosed |
| US-20110269752-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | PASTOR-FERNANDEZ JOAQUIN | 2011-11-03 | — | — | US | disclosed |
| WO-2011110545-A1 | IMIDAZO [1, 2 -A] PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011051342-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011051342-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157430-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PI4KB | GBA1 2953/4885HSD17B10 4521/4885ALDH1A1 3828/4885 |
| US-20250059172-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL | MC5R, CYP3A5, PTGIS | GBA1 901/4885HSD17B10 2284/4885ALDH1A1 889/4885 |
| US-11807650-B2 | NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN2C | GBA1 4068/4885HSD17B10 1959/4885ALDH1A1 2036/4885 |
| US-20240294546-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2C | GBA1 4068/4885HSD17B10 1959/4885ALDH1A1 2036/4885 |
| US-12358929-B2 | NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN2C | GBA1 4068/4885HSD17B10 1959/4885ALDH1A1 2036/4885 |
| US-20120220581-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | PDE12, PDE10A, PDE5A | GBA1 409/4885HSD17B10 39/4885ALDH1A1 484/4885 |
| US-20220153755-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2C | GBA1 4068/4885HSD17B10 1959/4885ALDH1A1 2036/4885 |
| US-20110269752-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | PDE12, PDE10A, PDE5A | GBA1 409/4885HSD17B10 39/4885ALDH1A1 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.